JCN Newswires
- Publisher:
- Japan Corporate News Network K.K.
- Publication date:
- 2018-10-17
- Copyright:
- COPYRIGHT Japan Corporate News Network K.K.
Publisher
Latest documents
- Japantastics Introduces Sato Mokko to the World -- A New Chapter in Japanese Artisanal Craftsmanship.
- BAE Systems and NEC Sign MoU to Strengthen Japan's Active Cyber Defence.
- Anime Tokyo Station Early Summer Festival.
- Eisai Announces Strategic Investment Supported by the UK Government's LSIMF.
- Honda to Begin Supplying Three High-output Models of the eGX Electric Power Unit Series for Commercial-Grade Work Equipment.
- Hitachi expands its work with OpenAI to accelerate AI-driven modernization and cybersecurity.
- Sharp to Introduce AQUOS R11 Smartphone.
- Fujitsu and IBM Japan collaborate on modernization to support enterprise digital transformation.
- Hitachi Energy expands zero-emission power portfolio with HyFlex Compact.
- Report verifying the net carbon impact of NEC's agricultural solution, CropScope, published as part of the Net Carbon Impact initiative promoted by the EU Green Digital Coalition.
Featured documents
- LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC).
- FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease.
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026.
- Showa Denko: Announcement Regarding the Planned Commencement of Tender Offer for Shares in Hitachi Chemical Company, Ltd.
- FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC).
- FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC).
- Showa Denko Maps Out New Medium-term Business Plan "The TOP 2021".
- Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer.
- SDK Formulates 'Long-term Vision (2021-2030) for Newly Integrated Company'.
- U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients.
